Trials / Terminated
TerminatedNCT00060515
RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease
An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (planned)
- Sponsor
- Repligen Corporation · Industry
- Sex
- All
- Age
- 3 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RG2133 (2',3',5'-tri-O-acetyluridine) |
Timeline
- First posted
- 2003-05-08
- Last updated
- 2005-08-05
Source: ClinicalTrials.gov record NCT00060515. Inclusion in this directory is not an endorsement.